Interpretation Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital.
Not bad, not a magic bullet, but reducing hospitalization rates from 16% to 11% is a win.
https://www.nytimes.com/2021/10/27/health/antidepressant-flu...
https://www.wsj.com/articles/antidepressant-significantly-re...
https://www.cnn.com/videos/health/2021/02/27/coronavirus-pos...
By comparison, I recall that some of the studies that championed ivermectin as a treatment for COVID included experiment participants who were dead before the studies began.